Edition:
India

Advanced Accelerator Applications SA (AAAP.OQ)

AAAP.OQ on NASDAQ Stock Exchange Global Select Market

81.99USD
19 Jan 2018
Change (% chg)

$0.08 (+0.10%)
Prev Close
$81.91
Open
$81.88
Day's High
$81.99
Day's Low
$81.88
Volume
48,536
Avg. Vol
168,371
52-wk High
$81.99
52-wk Low
$27.90

Summary

Name Age Since Current Position

Claudio Costamagna

61 2012 Chairman of the Board

Stefano Buono

49 Chief Executive Officer, Founder, Director

Heinz Mausli

52 2014 Chief Financial Officer

Gerard Ber

57 2014 Chief Operating Officer

Claude Hariton

59 2014 Head of Clinical Development

Maurizio Mariani

55 2009 Global Head of Pre-Clinical Research

Kapil Dhingra

58 2014 Independent Director

Steven Gannon

55 2014 Independent Director

Yvonne Greenstreet

54 2014 Independent Director

Christian Merle

60 2014 Independent Director

Leopoldo Zambeletti

2014 Independent Director

Christine Mikail

39 2017 Non-Executive Independent Director

Francois Nader

60 2016 Non-Executive Independent Director

Biographies

Name Description

Claudio Costamagna

Mr. Claudio Costamagna is Chairman of the Board of Advanced Accelerator Applications S.A. He is the Chairman of our board of directors and was appointed to our board in January 2010. He is the founder and Chairman of the financial advisory boutique CC&Co. and Chairman of Cassa Depositi e Prestiti S.p.A. (CDP). He also sits on the Board and is the Chair of the Compensation Committee of FTI Consulting Inc. a company listed on the NYSE. He previously held senior positions at Citigroup, Montedison, and most recently, Goldman Sachs, where he served until 2006 as Chairman of the Investment Banking division for Europe and the Middle East. He has served as Independent Board Member of several public companies including, among others, Luxottica Group, Bulgari S.p.A. and Virgin Group Holding. Mr. Costamagna holds a degree in Business Administration from Università Bocconi in Milan.

Stefano Buono

Mr. Stefano Buono is Chief Executive Officer, Founder, Director of the company. Prior to founding AAA in 2002, Mr. Buono worked as a physicist at the Centre for Advanced Studies, Research and Development, or CRS4. During his six years with CRS4, Mr. Buono headed a team of engineers working on different international research projects in the field of energy production and nuclear waste transmutation. For approximately ten years, he worked with Physics Nobel Laureate Carlo Rubbia at CERN, the world’s largest research laboratory for particle physics. He is the author of numerous scientific papers. Mr. Buono received his Master Degree in physics from the Universita degli Studi di Torino in Turin, Italy in 1991.

Heinz Mausli

Mr. Heinz Mausli is Chief Financial Officer of the company. He is the Chief Financial Officer and a former member of our board of directors from 2008 to 2014. Mr. Mäusli joined AAA in 2003. He also serves as a member of the boards of directors of several of AAA’s subsidiaries. Prior to joining AAA, Mr. Mäusli was a management consultant for Accenture from 1996 to 2001 and Gemini Consulting from 1995 to 1996. Mr. Mäusli received a master’s degree from the University of St. Gallen in St. Gallen, Switzerland in 1988 and a master’s degree in business administration from Columbia Business School in New York City, New York in 1994.

Gerard Ber

Mr. Gerard Ber is Chief Operating Officer of Advanced Accelerator Applications S.A. He is the Chief Operating Officer and a former member of our board of directors from 2002 to 2014. Mr. Ber joined AAA in 2002. Prior to joining AAA, Mr. Ber served as the Director of OM Pharma’s Western European group from 2000 to 2002, the Director General and Director of Marketing and Commerce for CIS Medipro from 1994 to 2000, and in various management roles at CIS Bio International from 1984 to 1994. He is also a member of the boards of directors of several of AAA’s subsidiaries. Mr. Ber received a PhD in pharmacy and a master’s degree in advanced studies in food science from the Université Scientifique et Médicale de Grenoble in Grenoble, France in 1983 and 1984, respectively, and a degree in marketing and international commerce from the Institut de Pharmacie Industrielle de Paris in Paris, France in 1984.

Claude Hariton

Mr. Claude A. Hariton is Head of Clinical Development of the company. Since February 2014 as Head of Clinical Development. Over the last 25 years, he has held senior positions in biotechnology and pharmaceutical companies in Switzerland, Canada, Australia, Germany, Spain and the United Kingdom, with his most recent positions including Vice President, Global Head of Regulatory Affairs at Mayne Pharma, Vice President, Clinical and Regulatory Affairs and Chief Medical Officer at Aeterna-Zentaris, Vice President, Scientific Affairs at Fresenius and Vice President, Global Head of R&D at ISDIN. Dr. Hariton received his PhD in neuroscience from the University of Sciences in Marseille, France in 1984 and conducted postdoctoral research at INSERM U278 also in Marseille, France. He received his DSc in Pharmacology from the University of Medicine in Marseille, France in 1988while leading drug development at Ciba Geigy and Novartis in Switzerland, and was appointed Associate Professor at the School of Medicine in Marseille, France in 1998.

Maurizio Mariani

Mr. Maurizio Franco Mariani is Global Head of Pre-Clinical Research of the company. he is the Global Head of Pre-Clinical Research and joined AAA in April 2009. Prior to joining AAA, Dr. Mariani was General Manager of Merck Serono RBM and Head of Exploratory Medicine for the Merck Serono Group. Additionally, over the last 20 years, he has held several senior positions in pharmaceutical companies, including at the Menarini Pharma Group in Italy and the Galdema Pharma Group in France, where he was the Head of Development. Dr. Mariani is a physician who received a degree in medicine and surgery from the Universita degli studi di Roma La Sapienza in Rome, Italy in 1983, a PhD in pharmacology from Temple University in Philadelphia, Pennsylvania in 1988 and a diploma from the American Board of Toxicology in Raleigh, North Carolina in 1991.

Kapil Dhingra

Dr. Kapil Dhingra, M.D. is Independent Director of Advanced Accelerator Applications S.A. Since March 2014. Dr. Dhingra founded and is the head of KAPital Consulting, a healthcare consulting firm. Prior to joining AAA, Dr. Dhingra worked for over 25 years in oncology clinical research and drug development. His experience includes nine years at Hoffman-La Roche, where he served in various positions, including Vice President, Head of the Oncology Disease Biology Leadership Team and Head of Oncology Clinical Development. Prior to that, he worked as a Senior Clinical Research Physician at Eli Lilly and Company. Dr. Dhingra specialized in internal medicine and medical oncology. He holds an MD (MBBS) degree from the All India Institute of Medical Sciences in New Delhi, India, with subsequent residency in internal medicine at Lincoln Medical and Mental Health Center in New York City, New York and New York Medical College in Valhalla, New York, and was a Fellow in hematology/oncology at Emory University School of Medicine in Atlanta, Georgia.

Steven Gannon

Mr. Steven R. Gannon is Independent Director of Advanced Accelerator Applications S.A. Since June 2014. He was a Senior Vice President and the Chief Financial Officer and Treasurer at Aptalis Pharma Inc. until February 2014, after which it was sold to Forest Laboratories. Prior to joining Aptalis Pharma Inc. in 2006, Mr. Gannon served as the Chief Financial Officer for Cryocath Technologies, Inc. from 1999 to 2006, as the Director of Finance and Administration of the Research Division of Astrazeneca Canada Inc. from 1996 to 1999, and as the Chief Financial Officer of Mallinckrodt Medical Inc.’s Canadian operations from 1989 to 1995. He received a bachelor of commerce in accounting and business systems from Concordia University in Montreal, Canada in 1983, and completed the Executive Program at the Richard Ivey School of Business at the University of Western Ontario in Ontario, Canada in 1995. He has been a chartered accountant since 1985.

Yvonne Greenstreet

Dr. Yvonne Greenstreet, M.D. is Independent Director of Advanced Accelerator Applications S.A. She has over 20 years of global experience in the pharmaceutical industry, where she has a proven track record as a business leader and drug developer. Dr. Greenstreet was a senior vice president and the Head of Medicines Development at Pfizer from 2010 to 2013. Prior to joining Pfizer, Dr. Greenstreet served in various roles at GlaxoSmithKline from 1992 to 2010, including Chief Medical Officer for Europe and Chief of Strategy. Dr. Greenstreet serves on the Advisory Board of the Bill and Melinda Gates Foundation and as a member of the board of directors of Pacira. She completed her medical training at the University of London Hospitals in London, United Kingdom in 1990, and received her MBChB from the University of Leeds in Leeds, United Kingdom in 1985. She subsequently completed a master’s degree in business administration at INSEAD in Fontainebleau, France in 1991.

Christian Merle

Mr. Christian Merle is Independent Director of Advanced Accelerator Applications S.A. He is the Managing Partner of Merle & Partners. Prior to founding Merle & Partners in 2014, Mr. Merle was the Chief Executive Officer of Banque Espirito Santo from 2007 to 2013, the Managing Partner of Gimar & Cie from 2003 to 2007 and the Chief Executive Officer of Banca Intesa from 1998 to 2003. Prior to joining Banca Intesa, he served in various roles at Credit Agricole, including as the Executive Vice President of Credit Agricole Indosuez. He also served in various roles in the French Treasury, including the Chief Representative in the United States from 1987 to 1990. He received his undergraduate degree from the Institut d’Etudes Politique de Paris in 1974 and a master’s degree in economics from the Université de Paris I-Panthéon Sorbonne in 1975, both in Paris, France.

Leopoldo Zambeletti

Mr. Leopoldo Zambeletti is Independent Director of Advanced Accelerator Applications S.A. He is an independent financial advisor in the Life Science sector. In this capacity he has advised various companies on corporate finance matters including advising Nogra Pharma in the largest ever out licensing to Celgene for a compound in development. Prior to becoming an advisor, Mr. Zambeletti was a managing director and Head of European, India and MENA Healthcare Investment Banking at Credit Suisse and a managing director and the Head of the Ultra High Net Worth group at Credit Suisse’s investment bank from 2007 to 2012. From 1994 to 2007, he held various positions at J.P. Morgan, including as Head of Healthcare Investment Banking. He received a bachelor’s degree in business administration from the Università Commerciale Luigi Bocconi in Milan, Italy in 1992. Mr. Zambeletti serves as a member of the board of directors of Nogra Pharma, Summit Therapeutics and Qardio. He is also a trustee of Saint Barts and the London Charity.

Christine Mikail

Ms. Christine Mikail is Non-Executive Independent Director of the company. She has over fifteen years of experience managing and advising a number of public and private biotech and pharmaceutical companies focusing in the legal and business development functions. Ms. Mikail is the founder of DCA Advisory where she is currently advising several start-up and private biotech companies. She is also an Adjunct Professor at the Rutgers Business School in New Jersey. From March 2015, to March 2017, she was Chief Administrative Officer, Head of External Business Development and Alliance Management, and General Counsel at Axovant Sciences, Inc., where she helped raise $362 million in one the largest biotech Initial Public Offerings. Prior to this, Ms. Mikail served as Senior Vice President of Legal Affairs, General Counsel and Secretary at NPS Pharmaceuticals, Inc.

Francois Nader

Dr. Francois E Nader, M.D. is Non-Executive Independent Director of the Company. He has over 30 years of experience in the global biopharmaceutical industry in senior operational and scientific roles. From 2008 to 2015, Dr. Nader served as the President and Chief Executive Officer of NPS Pharmaceuticals, Inc. and previously served as Chief Operating Officer in 2007, and Chief Medical and Commercial officer in 2006. During his tenure as CEO, Dr. Nader transformed NPS into a leading global biotechnology company focused on delivering innovative therapies to patients with rare diseases until Shire acquired the company for $5.2B in February 2015. Dr. Nader was recognized as the EY US National Life Science Entrepreneur of the Year ® in 2013. Before joining NPS, Dr. Nader was a venture partner at Care Capital. Prior to that, he served on the North America Leadership Team of Aventis and its predecessor companies holding a number of executive positions in the U.S. and Canada, including Senior Vice President, U.S. integrated healthcare markets and North America medical and regulatory affairs. Previously, he led the global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc. Dr. Nader earned his French Doctorate in Medicine from St. Joseph University in Lebanon in 1981 and his Physician Executive MBA from the University of Tennessee in 2000.